Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optune plus Bevacizumab in Bevacizumab-refractory Recurrent Glioblastoma
NCT02743078Phase 2Terminated
- Sponsor
- RTOG Foundation
- Start
- May 2017
- Primary completion
- Oct 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in glioblastoma (GBM), sponsored by RTOG Foundation. Started May 2017; status: terminated.
02
Drugs
bevacizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02743078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02743078.